

I hereby certify that this correspondence is being delivered with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patent and Trademarks, Washington, D.C. 20231 on May 8, 2002.

Theodore P. Cummings 40,973
Name of Attorney Registration No.
Signature of Attorney

COPY

#17
Pop
3/5/23

P&G Case 8043M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of Kester, et al.

: Confirmation No. 6353

Serial No. 09/827,834

: Group Art Unit 1761

Filed April 6, 2001

: Examiner K.J. Stiller

For COMPOSITIONS FOR REDUCING HYPERCHOLESTEROLEMIA AND CONTROLLING OF
POSTPRANDIAL BLOOD GLUCOSE AND INSULIN LEVELS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

Copies of the cited documents are enclosed.

Additional information is attached.


Respectfully submitted,

By

Theodore P. Cummings
Attorney or Agent for Applicant(s)
Registration No. 40,973
(513) 634-1906

Date: May 8, 2002

Customer No. 27752



COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
8004M	09/813,251	Wong, et al.	March 20, 2001
8005M	09/813,254	Wong, et al.	March 20, 2001
8036M	09/828,016	Prosise, et al.	April 6, 2001
8037M	09/827,863	Prosise, et al.	April 6, 2001
8038M	09/828,018	Prosise, et al.	April 6, 2001
8039M	09/827,802	Prosise, et al.	April 6, 2001
8040M	09/828,015	Prosise, et al.	April 6, 2001
8041M	09/827,436	Prosise, et al.	April 6, 2001